Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Nuo Therapeutics reported Q1 2026 total revenue of $1.3 million, a 169% increase year-over-year, driven by strong demand for its Aurix wound care product. The company narrowed its net operating loss to $446,000 from $745,000 in the prior year quarter, though it remains unprofitable with a net loss of $618,000.
Key figures
- Revenue
- 1302115
- Revenue Yoy
- 169%
- Cash
- 263827
- Gross profit
- 849727
- Total assets
- 1945669
- Product revenue
- 1224174
- Total liabilities
- 3329532
- Loan facility amount
- 1000000
- Distribution fee revenue
- 77941
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.